Skip to main content

Articles

Page 1 of 83

  1. Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor with a poor prognosis, marked by a postoperative recurrence rate of 50–60% and a 5-year survival rate of 8–30%. Abnormal tumor metabolism, particularl...

    Authors: Yanyu Gong, Liwen Chen, Hao Wang, Dijie Zheng, Futang Li, Changhao Wu, Yongning Li, Yazhu Deng, Zhiwei He and Chao Yu
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:151
  2. Serous endometrial cancer (SEC) is a genomically and morphologically distinct endometrial cancer (EC) subtype with a poor progression-free and overall survival. The development of novel therapies is needed to ...

    Authors: Xiaonan Hou, Valentina Zanfagnin, Conway Xu, Erik Jessen, Yuanhang Liu, Chen Wang, Yajue Huang, Shaun D. Fontaine, Daniel V. Santi, Gerardo Colon-Otero, Sarah E. Gill, Gretchen E. Glaser, Kristina A. Butler, Jamie N. Bakkum-Gamez, Sean C. Dowdy, Ann L. Oberg…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:150
  3. Copper accumulation triggers mitochondrial-driven cell death, known as cuproptosis, offering a promising mechanism for targeted cancer therapy. Recent studies have highlighted the critical role of intratumoral...

    Authors: Pengyu Wang, Weihua Guo, Shuyue Liu, Shouyi Li, Jiaqi Li, Bowen Ding, Fengyi Yin, Yang Yang, Xingjiang Li, Pei Cao, Chaozhe Ma, Wanying Zhang, Yidan Song, Yating Geng, Lantao Liu, Jing Hu…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:149
  4. Immunotherapy, notably the immune checkpoint blockade (ICB), has demonstrated significant promise in the management of diverse neoplasms. However, the PD-1 inhibitor has exhibited suboptimal objective response...

    Authors: Hai Xu, Shuo Li, Yifan Liu, Yoon-Young Sung, Yong Zhou and Huikun Wu
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:148
  5. Although tumor immunotherapy has emerged as a promising treatment modality, it faces significant challenges stemming from the immunosuppressive characteristics of the tumor microenvironment (TME), the low immu...

    Authors: Chuan Wu, Mingquan Gao, Weidong Xiao, Xie Huang, Xinrui Yang, Zifei Wu, Xudong Yu, Banghui Mo, Zaizhi Du, Ziqian Shang, Jing Liu, Can Shi, Rong Li, Shenglin Luo and Weidong Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:147
  6. Complex host-virus interactions account for adaptive and innate immunity dysfunctions and viral cccDNA mini-chromosome persistence, key features of HBV chronicity and challenges for HBV cure. The extent of HBV...

    Authors: Vincenzo Alfano, Giuseppe Rubens Pascucci, Giacomo Corleone, Massimiliano Cocca, Francesca De Nicola, Océane Floriot, Alexia Paturel, Francesca Casuscelli Di Tocco, Claude Caron de Fromentel, Philippe Merle, Michel Rivoire, Massimo Levrero and Francesca Guerrieri
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:146
  7. Despite the significant advances in the development of immune checkpoint inhibitors (ICI), primary and acquired ICI resistance remains the primary impediment to effective cancer immunotherapy. Residing in the ...

    Authors: Yan Yang, Sijia Li, Kenneth K.W. To, Shuangli Zhu, Fang Wang and Liwu Fu
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:145
  8. Hepatocellular carcinoma (HCC) is associated with a poor 5-year survival mainly due to detection at late stages. Better non-invasive surveillance methods are needed to improve early detection and maximize surv...

    Authors: Siyu Fu, Ruben G. Boers, Joachim B. Boers, Pam E. van der Meeren, Jean Helmijr, Vanja de Weerd, Michail Doukas, Maurice Jansen, Bettina E. Hansen, Roeland F. de Wilde, Dave Sprengers, Joost Gribnau, Saskia M. Wilting, José D. Debes and Andre Boonstra
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:144
  9. The potential influence of radical prostatectomy on tumor cell release into the blood circulation is an under-investigated area.

    Authors: Gresa Emurlai, Randi M. Pose, Nikhil Kalra, Cornelia Coith, Sandra Lenz, Pierre Tennstedt, Markus Graefen, Stefan Werner, Sabine Riethdorf, Derya Tilki, Simon A. Joosse and Klaus Pantel
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:143
  10. Myofibroblastic cancer-associated fibroblasts (CAF) in tumor stroma serves as an independent poor prognostic indicator, supporting higher stemness in oral cancer; however, the underlying biology is not fully c...

    Authors: Paromita Mitra, Uday Saha, Kingsly Joshua Stephen, Priyanka Prasad, Subhashree Jena, Ankit Kumar Patel, Harshavardhan BV, Santosh Kumar Mondal, Sillarine Kurkalang, Sumitava Roy, Arnab Ghosh, Shantanu Saha Roy, Jayasri Das Sarma, Nidhan Kumar Biswas, Moulinath Acharya, Rajeev Sharan…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:142
  11. Tumors often evade immune surveillance by limiting T cell infiltration. In non-small cell lung cancer (NSCLC), increased infiltration of CD8+ T cells is associated with a favorable response to immunotherapy. Whil...

    Authors: Jiali Wang, Yunlong Jia, Tianxu Liu, Xinyan Liu, Shuxian Yin, Jiaqi Chen, Xiaoqing Xu, Yi Zhang and Lihua Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:141
  12. Liquid biopsy offers a noninvasive method to identify and monitor tumor-derived biomarkers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, microRNAs, and tumor-educated plat...

    Authors: Canio Martinelli, Alfredo Ercoli, Giuseppe Vizzielli, Sharon Raffaella Burk, Maria Cuomo, Vrunda Satasiya, Housem Kacem, Simone Braccia, Giulio Mazzarotti, Irene Miriello, Manuela Nana Tchamou, Stefano Restaino, Martina Arcieri, Alice Poli, Veronica Tius, Silvana Parisi…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:140
  13. Lenvatinib, a tyrosine kinase receptor inhibitor, has emerged as a frontline therapeutic strategy for the management of advanced hepatocellular carcinoma (HCC). However, the modest response rate observed with ...

    Authors: Bixing Zhao, Yang Zhou, Niangmei Cheng, Xiaoyuan Zheng, Geng Chen, Xin Qi, Xiangzhi Zhang, Fei Wang, Qiuyu Zhuang, Yehuda G. Assaraf, Xiaolong Liu, Yingchao Wang and Yongyi Zeng
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:139
  14. Extracellular vesicles (EVs), particularly engineered variants, have emerged as promising tools in cancer immunotherapy due to their inherent ability to modulate immune responses and deliver therapeutic agents...

    Authors: Zheng Gong, Cheng Cheng, Chaonan Sun and Xiaoli Cheng
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:138
  15. IL-33 is an epithelial-derived alarmin with various roles in cancer. In melanoma, endogenous and exogenous IL-33 exert anti-tumor effects through the stimulation of several immune effector cells. In this study...

    Authors: Francesco Noto, Jacopo Mancini, Adriana Rosa Gambardella, Christina Curcio, Adele De Ninno, Sara Andreone, Carla Buccione, Maria Teresa D’Urso, Daniele Macchia, Anna Maria Pacca, Massimo Spada, Luca Businaro, Claudia Afferni, Fabrizio Mattei and Giovanna Schiavoni
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:137
  16. There are no validated biomarkers for assessing hepatocellular carcinoma (HCC) treatment response (TR). Extracellular vesicles (EVs) are promising circulating biomarkers that may detect minimal residual diseas...

    Authors: Chen Zhao, Yi-Te Lee, Andrew Melehy, Minhyung Kim, Jacqueline Ziqian Yang, Ceng Zhang, Jina Kim, Ryan Y. Zhang, Junseok Lee, Hyoyong Kim, Yong Ju, Yuan-Jen Tsai, Xianghong Jasmine Zhou, Steven-Huy B. Han, Saeed Sadeghi, Richard S. Finn…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:136
  17. A critical step in the metastatic cascade is the survival of circulating tumor cells (CTCs) within the bloodstream. Although interactions between CTCs and various hematopoietic cells have been described, the r...

    Authors: Thais Pereira-Veiga, Celso Yáñez-Gómez, Aleksi Pekkarinen, Carmen Abuín, Christine Blechner, Miriam González-Conde, Christian Mess, Sabine Vidal-y-Sy, Ayham Moustafa, Bente Siebels, Ana B. Dávila-Ibáñez, Pablo Cabezas-Sainz, Maider Santos, Laura Sánchez, Joao Gorgulho, Julian Götze…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:134
  18. Diffuse midline glioma (DMG) is an aggressive pediatric brain tumor with limited treatment options. Although natural killer (NK) cell-based immunotherapy is promising, its efficacy remains limited, necessitati...

    Authors: Yuxuan Deng, Jinqiu Liu, Zhuonan Pu, Yi Wang, Tian Li, Zhuang Jiang, Luyang Xie, Xiaoli Zhang, YingDan Chen, Mingxu Yang, Chao Du, Shuyu Hao, Nan Ji, Zhengping Zhuang, Jie Feng and Liwei Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:133
  19. Immune checkpoint inhibitors (ICIs) present clinical benefits in many cancer patients but invariably fail in glioblastoma (GBM), the most common and deadly primary brain tumor. The lack of ICIs efficacy in GBM...

    Authors: Aleksandra Ellert-Miklaszewska, Paulina Pilanc, Katarzyna Poleszak, Adria-Jaume Roura, Salwador Cyranowski, Mitrajit Ghosh, Szymon Baluszek, Maria Pasierbinska, Bartłomiej Gielniewski, Julian Swatler, Yuliana Hovorova, Kamil Wojnicki and Bozena Kaminska
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:132
  20. This review discusses reprogramming the breast tumor immune microenvironment from an immunosuppressive cold state to an immunologically active hot state. A complex interplay is revealed, in which the accumulat...

    Authors: Saber Imani, Reyhaneh Farghadani, Ghazaal Roozitalab, Mazaher Maghsoudloo, Mahdieh Emadi, Atefeh Moradi, Behnaz Abedi and Parham Jabbarzadeh Kaboli
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:131
  21. Hepatocellular carcinoma (HCC), the most prevalent type of primary liver cancer, is linked to elevated global incidence and mortality rates. Elucidating the intricate molecular pathways that drive the progress...

    Authors: Xing Ren, Wenna Yang, Xiuli Yan and Hui Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:130
  22. Pancreatic ductal adenocarcinoma (PDAC) is among the cancer types with poorest prognosis and survival rates primarily due to resistance to standard-of-care therapies, including gemcitabine (GEM) and olaparib. ...

    Authors: Juliana Calheiros, Rita Silva, Filipa Barbosa, João Morais, Sara Reis Moura, Sofia Almeida, Elena Fiorini, Silva Mulhovo, Tatiana Q. Aguiar, Tao Wang, Sara Ricardo, Maria Inês Almeida, Lucília Domingues, Sonia A. Melo, Vincenzo Corbo, Maria-José U. Ferreira…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:129
  23. Lung cancer remains one of the most challenging diseases to treat due to its heterogeneity. Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutations are genetic drivers in numerous cancer types including lu...

    Authors: İsa Taş, Ruben Jacobs, Juliane Albrecht, Sebastian A. Barrientos, Josephine Åberg, Wondossen Sime, Hans Brunnström, Helena Persson, Julhash U. Kazi and Ramin Massoumi
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:128
  24. Cancer-associated fibroblasts (CAFs) are tissue residing cells within the tumor microenvironment (TME). Stromal CAFs have been shown to be associated with poor prognosis and tumor progression in several solid ...

    Authors: Franziska Weber, Kim-Lea Reese, Klaus Pantel and Daniel J. Smit
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:127
  25. MicroRNAs (miRNAs) have emerged as pivotal regulators in cancer biology, influencing tumorigenesis, progression, and resistance to therapy. Their ability to modulate multiple oncogenic and tumor-suppressive pa...

    Authors: Maria Teresa Di Martino, Pierosandro Tagliaferri and Pierfrancesco Tassone
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:126
  26. The plasma cell malignancy multiple myeloma (MM) remains incurable due to the inevitable development of drug resistance (DR). Epigenetic modifiers are frequently mutated or deregulated in MM patients, contribu...

    Authors: Catharina Muylaert, Lien Ann Van Hemelrijck, Arne Van der Vreken, Robbe Heestermans, Hatice Satilmis, Emma Verheye, Elina Alaterre, Catharina Olsen, Nathan De Beule, Kim De Veirman, Eline Menu, Karin Vanderkerken, Jérôme Moreaux and Elke De Bruyne
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:125
  27. Uveal melanoma is an aggressive ocular malignancy. Early molecular characterisation of primary tumours is crucial to identify those at risk of metastatic dissemination. Although tumour biopsies are being taken...

    Authors: R. J. Nell, M. Versluis, N. V. Menger, M. C. Gelmi, T. H.K. Vu, R. M. Verdijk, G. P.M. Luyten, M. J. Jager and P. A. van der Velden
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:124
  28. Authors: Seung Hee Choi, Hye Jung Jang, Joo Dong Park, Ki Seo Ryu, Eunchong Maeng, Seohyun Cho, Hail Park, Hae-Yun Jung and Kyung-Soon Park
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:123

    The original article was published in Journal of Experimental & Clinical Cancer Research 2025 44:48

  29. Authors: Daniele Cretella, Andrea Ravelli, Claudia Fumarola, Silvia La Monica, Graziana Digiacomo, Andrea Cavazzoni, Roberta Alfieri, Alessandra Biondi, Daniele Generali, Mara Bonelli and Pier Giorgio Petronini
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:122

    The original article was published in Journal of Experimental & Clinical Cancer Research 2018 37:72

  30. Metastasis is a leading cause of colorectal cancer (CRC)-related mortality, yet its molecular mechanisms remain poorly understood. Long noncoding RNAs (lncRNAs) have emerged as critical regulators of CRC metas...

    Authors: Junwen Qi, Tao Jiang, Bowen Liu, Qihang Hu, Junnan Chen, Ning Ma, Yixin Xu, Hu Song and Jun Song
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:121
  31. Intrinsic and acquired resistance to second-generation anti-androgens pose a significant clinical challenge in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Novel biomarkers to pred...

    Authors: Maibritt Nørgaard, Maria Rusan, Karoline Kondrup, Ea Marie Givskov Sørensen, Simone Weiss, Marianne Trier Bjerre, Jacob Fredsøe, Søren Vang, Jørgen Bjerggaard Jensen, Bram De Laere, Henrik Grönberg, Michael Borre, Johan Lindberg and Karina Dalsgaard Sørensen
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:120
  32. Immune checkpoint inhibitors (ICIs), such as anti-Cytotoxic T-Lymphocyte Antigen 4(CTLA-4) and anti-Programmed cell death protein 1 (PD-1) agents, have improved the prognosis of patients with metastatic melano...

    Authors: Susan Costantini, Gabriele Madonna, Mariaelena Capone, Elena Di Gennaro, Palmina Bagnara, Federica Renza, Domenico Mallardo, Roberta Affatato, Carlo Vitagliano, Marilena Romanelli, Marilena Tuffanelli, Ester Simeone, Gennaro Ciliberto, Paolo A. Ascierto and Alfredo Budillon
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:119
  33. Natural killer (NK) play a key role in controlling tumor dissemination by mediating cytotoxicity towards cancer cells without the need of education. These cells are pivotal in eliminating circulating tumor cel...

    Authors: Doryan Masmoudi, Martin Villalba and Catherine Alix-Panabières
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:118
  34. Activated hepatic stellate cells (HSCs) induce alternative (M2) polarization of macrophages and contribute to the progression of fibrosis and hepatocellular carcinoma (HCC). However, the effects of small extra...

    Authors: Yufeng Sun, Min Zhao, Li Cheng, Xiaoqian He, Shiqi Shen, Jiaying Lv, Junyu Zhang, Qian Shao, Wenxuan Yin, Fengbo Zhao, Rui Sun, Peng Lu, Yuhua Ji, Xin Wei Wang and Juling Ji
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:117
  35. Authors: Qianghua Zhou, Xu Chen, Kai Yao, Yangjie Zhang, Haixia He, Hao Huang, Hao Chen, Shengmeng Peng, Ming Huang, Liang Cheng, Qiang Zhang, Ruihui Xie, Kaiwen Li, Tianxin Lin and Hai Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:116

    The original article was published in Journal of Experimental & Clinical Cancer Research 2023 42:195

  36. Authors: Luis Enrique Cortés-Hernández, Zahra Eslami-S, Aurore Attina, Silvia Batista, Laure Cayrefourcq, Jérôme Vialeret, Dolores Di Vizio, Christophe Hirtz, Bruno Costa-Silva and Catherine Alix-Panabières
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:115

    The original article was published in Journal of Experimental & Clinical Cancer Research 2025 44:102

  37. Acute myeloid leukemia (AML) is a highly aggressive cancer with a 5-year survival rate of less than 35%. It is characterized by significant drug resistance and abnormal energy metabolism. Mitochondrial dynamic...

    Authors: Su Jung Park, Claudia Cerella, Jin Mo Kang, Jinyoung Byun, David Kum, Barbora Orlikova-Boyer, Anne Lorant, Michael Schnekenburger, Ali Al-Mourabit, Christo Christov, Juyong Lee, Byung Woo Han and Marc Diederich
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:114
  38. Regulatory T cells (Tregs) are the main immunosuppressive cells in tumor immune microenvironment (TIME). However, systemic Treg depletion is not favored due to the crucial role of Tregs in the maintenance of i...

    Authors: Binle Tian, Zhilong Wang, Mei Cao, Na Wang, Xuebing Jia, Yuanyuan Zhang, Jingyi Zhou, Sijia Liu, Wen Zhang, Xiao Dong, Zheng Li, Junli Xue, JianFei Wang, Guo-Huang Fan and Qi Li
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:113
  39. The progression and recurrence are the fatal prognostic factors in glioma patients. However, the therapeutic role and potential mechanism of TRAF7 in glioma patients remain largely unknown.

    Authors: Yu Chen, Tongyu Zhou, Rongrong Zhou, Wen Sun, Yan Li, Qiyi Zhou, Dongcheng Xu, Yuxin Zhao, Peihao Hu, Jingrui Liang, Yumeng Zhang, Bin Zhong, Juncheng Yao and Di Jing
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:112
  40. New biomarkers for the detection and monitoring of aggressive variant prostate cancer (AVPC) including therapy-induced neuroendocrine prostate cancer (NEPC) are urgently needed, as measuring prostate-specific ...

    Authors: Lina Bergmann, Sarah Greimeier, Sabine Riethdorf, Tina Rohlfing, Moritz Kaune, Tobias Busenbender, Nadja Strewinsky, Sergey Dyshlovoy, Simon Joosse, Sven Peine, Klaus Pantel, Gunhild von Amsberg and Stefan Werner
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:111
  41. Lung cancer is a serious threat to human life and health, but effective screening and treatment methods are lacking. Circular RNAs (circRNAs) have important biological functions and are closely related to tumo...

    Authors: Haotian Xu, Qingyun Zhao, Dunyu Cai, Xingcai Chen, Xiaodong Zhou, Yihong Gao, Jiaxi Wu, Shengyi Yuan, Deqing Li, Ruirui Zhang, Wenyi Peng, Gang Li and Aruo Nan
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:110
  42. Inflammasomes are multi-protein complexes that detect pathogenic and damage-associated molecular patterns, activating caspase-1, pyroptosis, and the maturation of pro-inflammatory cytokines such as IL-1β and I...

    Authors: Vivek Singh, Saba Ubaid, Mohammad Kashif, Tanvi Singh, Gaurav Singh, Roma Pahwa and Anand Singh
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:109
  43. Neutrophil extracellular traps (NETs) are composed of DNA chains from neutrophils and associated proteolytic enzymes, which play an important role in cancer metastasis. However, the molecular mechanism of NET-...

    Authors: Shuai Yan, Wenxi Zhao, Juntong Du, Lizhi Teng, Tong Yu, Peng Xu, Jiangnan Liu, Ru Yang, Yuhan Dong, Hongyue Wang, Lingran Lu and Weiyang Tao
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:108
  44. Addressing the challenges of identifying suitable targets and effective delivery strategies is critical in pursuing therapeutic solutions for glioblastoma (GBM). This study focuses on the therapeutic potential...

    Authors: Po-Fu Yueh, I-Tsang Chiang, Yueh-Shan Weng, Yu-Chang Liu, Raymond C. B. Wong, Cheng-Yu Chen, Justin Bo-Kai Hsu, Long-Bin Jeng, Woei-Cherng Shyu and Fei-Ting Hsu
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:107
  45. KRAS is the most frequently mutated oncogene in human cancers, with KRASG12C being a prevalent driver mutation in 12–13% non-small cell lung cancer (NSCLC) cases. Despite breakthroughs in KRASG12C inhibitors such...

    Authors: Jianzhuang Wu, Kexin Xie, Yixuan Zhang, Weiyi Zhang, Rongjie Cheng, Yaliang Zhang, Yugui Xia, Tongyan Liu, Rong Yin, Yudong Qiu, Tao Xu, Rutian Li, Qi Sun and Chao Yan
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:106
  46. Prostate cancer (PCa) is the second most common type of tumor diagnosed in men and the fifth leading cause of cancer-related death in male patients. The response of metastatic disease to standard treatment is ...

    Authors: Ielizaveta Gorodetska, Vasyl Lukiyanchuk, Marta Gawin, Myroslava Sliusar, Annett Linge, Fabian Lohaus, Tobias Hölscher, Kati Erdmann, Susanne Fuessel, Angelika Borkowetz, Anna Wojakowska, Daniel Fochtman, Mark Reardon, Ananya Choudhury, Yasmin Antonelli, Aldo Leal-Egaña…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:105
  47. AMP-activated protein kinase (AMPK) is an energy sensor that regulates cellular metabolic activity. We hypothesized that in glioblastoma (GB), AMPK plays a pivotal role in balancing metabolism under conditions...

    Authors: Nadja I. Lorenz, Benedikt Sauer, Hans Urban, Jan-Béla Weinem, Bhavesh S. Parmar, Pia S. Zeiner, Maja I. Strecker, Dorothea Schulte, Michel Mittelbronn, Tijna Alekseeva, Lisa Sevenich, Patrick N. Harter, Christian Münch, Joachim P. Steinbach, Anna-Luisa Luger, Dieter Henrik Heiland…
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:104
  48. Perineural invasion (PNI) is a hallmark feature of pancreatic ductal adenocarcinoma (PDAC), which occurs at a high incidence and significantly contributes to PDAC lethality and poor survival. Despite its preva...

    Authors: Leyi Huang, Yanan Lu, Rihua He, Xiaofeng Guo, Jiajia Zhou, Zhiqiang Fu, Jingwen Li, Jianping Liu, Rufu Chen, Yu Zhou and Quanbo Zhou
    Citation: Journal of Experimental & Clinical Cancer Research 2025 44:103

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 11.4
    5-year Journal Impact Factor: 11.4
    Source Normalized Impact per Paper (SNIP): 1.770
    SCImago Journal Rank (SJR): 2.806

    Speed 2024
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 96

    Usage 2024
    Downloads: 4,059,655
    Altmetric mentions: 2,197